Literature DB >> 6311239

Blood neutrophil function in primary myelodysplastic syndromes.

M A Boogaerts, V Nelissen, C Roelant, W Goossens.   

Abstract

Ten different tests of blood neutrophil function were studied in 20 patients with primary myelodysplastic syndromes (PMDS). The patients were selected according to the new diagnostic criteria for PMDS of the FAB-cooperation group. Impairments of granulocyte functions were found in all patients. Moreover, several steps in the mobilization of granulocytes at the site of injury seemed to be affected: decreased adhesion (P less than 0.05), deficient chemotaxis (P less than 0.05), decreased enzyme content (P less than 0.001), 'slower' chemiluminescence (P less than 0.005), decreased phagocytosis (P less than 0.05) and impaired microbicidal capacity (P less than 0.025). No significant correlation between disease category and severity of granulocyte dysfunction was discerned, though an increasing number of blasts was associated with more severe granulocytic disability. Results in seven patients with abnormal karyotypes were not significantly different from 13 others with normal karyotypes. Our results indicate that defects in blood neutrophil function are a common feature in PMDS and might account for the increased frequency of infection in these patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6311239     DOI: 10.1111/j.1365-2141.1983.tb01241.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  23 in total

1.  Ability of recombinant interferon gamma in vitro to restore the defective polymorphonuclear-cell- but not lymphocyte-mediated cytotoxic activities in patients with myelodysplastic syndromes.

Authors:  G De Sanctis; V Bottari; A Frezzolini; M Ficcardi; G De Rossi; M C Petti; F Mandelli; L Fontana
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Monocyte function in patients with myelodysplastic syndrome.

Authors:  Daniel A Pollyea; Brenna R Hedin; Brian P O'Connor; Scott Alper
Journal:  J Leukoc Biol       Date:  2018-04-14       Impact factor: 4.962

3.  Granulocyte and monocyte surface membrane markers in the myelodysplastic syndromes.

Authors:  R E Clark; T G Hoy; A Jacobs
Journal:  J Clin Pathol       Date:  1985-03       Impact factor: 3.411

4.  Pyogenic abscesses in the myelodysplastic syndrome.

Authors:  P J Williamson; D G Oscier; G J Mufti; T J Hamblin
Journal:  BMJ       Date:  1989-08-05

Review 5.  The regulatory role of serum response factor pathway in neutrophil inflammatory response.

Authors:  Ashley Taylor; Stephanie Halene
Journal:  Curr Opin Hematol       Date:  2015-01       Impact factor: 3.284

Review 6.  The myelodysplastic syndromes.

Authors:  D M Layton; G J Mufti
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-25

Review 7.  Myelodysplastic syndromes.

Authors:  D C Doll; A F List
Journal:  West J Med       Date:  1989-08

8.  Defective host defence mechanisms in a family with hypocalciuric hypercalcaemia and coexisting interstitial lung disease.

Authors:  J Auwerx; M Boogaerts; J L Ceuppens; M Demedts
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

9.  Superoxide anion production and expression of cytochrome b 558 by neutrophils are impaired in some patients with myelodysplastic syndrome.

Authors:  Y Itoh; T Kuratsuji; S Aizawa; M Sai; K Ohyashiki; K Toyama
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

10.  Improvement of chronic osteomyelitis after granulocyte colony stimulating factor.

Authors:  Michael I Pearce; Ann Cuthbert; Guy Porter; Paul R J Ames
Journal:  Indian J Hematol Blood Transfus       Date:  2011-12-11       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.